Clinical Rheumatology

, Volume 33, Issue 3, pp 397–402 | Cite as

Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis

  • Hye-In Ji
  • Sang-Hoon Lee
  • Ran Song
  • Hyung-In Yang
  • Yeon-Ah Lee
  • Seung-Jae Hong
  • Somi Kim
  • Yong-Beom Park
  • Soo-Kon Lee
  • Myung Chul Yoo
  • Kyoung Soo Kim
Brief Report
First Online:
Received:
Revised:
Accepted:

Abstract

Osteopontin (OPN) is known to be significantly involved in the pathogenesis of rheumatoid arthritis (RA). This study aimed to evaluate if the serum concentration of OPN in patients with RA before and after therapeutic treatments was correlated to disease activity and response to therapy. Blood samples from 40 patients with RA were collected at baseline and six months after starting treatment with disease-modifying antirheumatic drugs (DMARDs) and/or tumor necrosis factor (TNF)-α blockers. Serum levels of OPN were measured by ELISA. At baseline, the serum OPN level in RA patients was significantly higher than that of the healthy group. The OPN level at baseline in RA patients with severe disease activity as evaluated by DAS28 was slightly higher than that of those with moderate disease activity. The serum OPN level in RA patients was not significantly correlated with the DAS28 level. The serum OPN level in both responders and non-responders after therapy was significantly decreased regardless of responsiveness to therapy. Also, the OPN level at baseline did not affect the responsiveness to therapeutic treatments. In conclusion, serum OPN level was not correlated with disease activity or responsiveness of RA patients to therapeutic treatments.

Keywords

Disease-modifying antirheumatic drugs (DMARDs) Osteopontin (OPN) Rheumatoid arthritis (RA) TNF blocker 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011–0009061) and Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102065).

Disclosures

None.

References

  1. 1.
    McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7(6):429–442PubMedCrossRefGoogle Scholar
  2. 2.
    Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O (2011) What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 7(9):528–536PubMedCrossRefGoogle Scholar
  3. 3.
    Zheng W, Li R, Pan H, He D, Xu R, Guo TB, Guo Y, Zhang JZ (2009) Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 60(7):1957–1965PubMedCrossRefGoogle Scholar
  4. 4.
    Xu G, Sun W, He D, Wang L, Zheng W, Nie H, Ni L, Zhang D, Li N, Zhang J (2005) Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 32(3):410–416PubMedGoogle Scholar
  5. 5.
    Braitch M, Constantinescu CS (2010) The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflamm Allergy Drug Targets 9(4):249–256PubMedCrossRefGoogle Scholar
  6. 6.
    Frenzel DF, Weiss JM (2011) Osteopontin and allergic disease: pathophysiology and implications for diagnostics and therapy. Expert Rev Clin Immunol 7(1):93–109PubMedCrossRefGoogle Scholar
  7. 7.
    Waller AH, Sanchez-Ross M, Kaluski E, Klapholz M (2010) Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiol Rev 18(3):125–131PubMedCrossRefGoogle Scholar
  8. 8.
    Scatena M, Liaw L, Giachelli CM (2007) Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27(11):2302–2309PubMedCrossRefGoogle Scholar
  9. 9.
    Hasegawa M, Nakoshi Y, Iino T, Sudo A, Segawa T, Maeda M, Yoshida T, Uchida A (2009) Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis. J Rheumatol 36(2):240–245PubMedCrossRefGoogle Scholar
  10. 10.
    Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19(5–6):333–345PubMedCrossRefGoogle Scholar
  11. 11.
    Morimoto J, Kon S, Matsui Y, Uede T (2010) Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr Drug Targets 11(4):494–505PubMedCrossRefGoogle Scholar
  12. 12.
    Masi L, Ricci L, Zulian F, Del Monte F, Simonini G, Capannini S, De Martino M, Brandi ML, Falcini F (2009) Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis. J Rheumatol 36(10):2308–2313PubMedCrossRefGoogle Scholar
  13. 13.
    Straburzynska-Lupa A, Nowak A, Romanowski W, Korman P, Pilaczynska-Szczesniak L (2013) A study of the link between bone turnover markers and bone mineral density with inflammation and body mass in postmenopausal women with active rheumatoid arthritis. J Bone Miner Metab 31(2):169–176PubMedCrossRefGoogle Scholar
  14. 14.
    Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK (2008) Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 47(12):1775–1779CrossRefGoogle Scholar
  15. 15.
    Jacobs JP, Pettit AR, Shinohara ML, Jansson M, Cantor H, Gravallese EM, Mathis D, Benoist C (2004) Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis. Arthritis Rheum 50(8):2685–2694PubMedCrossRefGoogle Scholar
  16. 16.
    Ishii T, Ohshima S, Ishida T, Mima T, Tabunoki Y, Kobayashi H, Maeda M, Uede T, Liaw L, Kinoshita N et al (2004) Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Biochem Biophys Res Commun 316(3):809–815PubMedCrossRefGoogle Scholar
  17. 17.
    Boumans MJ, Houbiers JG, Verschueren P, Ishikura H, Westhovens R, Brouwer E, Rojkovich B, Kelly S, den Adel M, Isaacs J et al (2012) Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann Rheum Dis 71(2):180–185PubMedCrossRefGoogle Scholar
  18. 18.
    Gao SG, Li KH, Zeng KB, Tu M, Xu M, Lei GH (2010) Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients. Osteoarthritis Cartilage 18(1):82–87PubMedCrossRefGoogle Scholar
  19. 19.
    Honsawek S, Tanavalee A, Sakdinakiattikoon M, Chayanupatkul M, Yuktanandana P (2009) Correlation of plasma and synovial fluid osteopontin with disease severity in knee osteoarthritis. Clin Biochem 42(9):808–812PubMedCrossRefGoogle Scholar
  20. 20.
    Naldini A, Leali D, Pucci A, Morena E, Carraro F, Nico B, Ribatti D, Presta M (2006) Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol 177(7):4267–4270PubMedGoogle Scholar
  21. 21.
    Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16(2):79–87PubMedCrossRefGoogle Scholar
  22. 22.
    Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, Ludvik B, Silberhumer GR, Prager G et al (2008) Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 149(3):1350–1357PubMedCrossRefGoogle Scholar
  23. 23.
    Gomez-Ambrosi J, Catalan V, Ramirez B, Rodriguez A, Colina I, Silva C, Rotellar F, Mugueta C, Gil MJ, Cienfuegos JA et al (2007) Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 92(9):3719–3727PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2013

Authors and Affiliations

  • Hye-In Ji
    • 1
  • Sang-Hoon Lee
    • 2
  • Ran Song
    • 2
  • Hyung-In Yang
    • 2
  • Yeon-Ah Lee
    • 3
  • Seung-Jae Hong
    • 3
  • Somi Kim
    • 3
  • Yong-Beom Park
    • 4
  • Soo-Kon Lee
    • 4
  • Myung Chul Yoo
    • 1
  • Kyoung Soo Kim
    • 1
  1. 1.East-West Bone & Joint Research InstituteKyung Hee UniversitySeoulRepublic of Korea
  2. 2.Division of Rheumatology, Department of Internal MedicineKyung Hee University Hospital at GandongSeoulRepublic of Korea
  3. 3.Division of Rheumatology, Department of Internal Medicine, College of MedicineKyung Hee UniversitySeoulRepublic of Korea
  4. 4.Divsion of Rheumatology, Department of Internal MedicineYonsei University College of MedicineSeoulRepublic of Korea

Personalised recommendations